Literature DB >> 10868621

Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants.

M Engstrand1, C Tournay, M A Peyrat, B M Eriksson, J Wadström, B Z Wirgart, F Romagné, M Bonneville, T H Tötterman, O Korsgren.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) is a ubiquitous herpesvirus that infects 50-90% of individuals in different populations. After primary infection, the virus persists latently in myeloid cells under the control of specific T-cells. Reactivation of CMV infection may cause lethal organ dysfunction and is frequently seen in immunosuppressed individuals. CD8+ cytotoxic T-cells (CTL) have a primary role in suppressing CMV reactivation, and the dominating CTL response is directed against pp65.
METHODS: MHC tetramers, that is, complexes between HLA class I (or class II) molecules and antigenic peptides conjugated to fluorochromes allow the direct visualization of antigen-specific receptor-carrying T-cells using flow cytometry. We constructed a novel MHC tetramer for identification of CMVpp65-specific CD8+ T-cells using HLA-A2 molecules folded with the immunodominant NLVPMVATV peptide.
RESULTS: The A2/pp65 tetramer specifically stained CMV-directed T-cell lines, and sorted cells showed CMV-specific cytotoxicity. High proportions (0.1-9%) of the CD8+ T-cells were A2/pp65 tetramer+ in healthy HLA-A2+ CMV carriers and in immunosuppressed kidney transplant patients with latent infection. Patients with reactivated CMV infection exhibited up to 15% A2/pp65 tetramer+ cells, which seemed to correlate with CMV load over time. A2/pp65 tetramer+ cells expressed T-cell activation markers.
CONCLUSIONS: The construction of a novel A2/pp65 MHC tetramer enabled the design of a rapid and precise flow cytometric method allowing quantitative and qualitative analysis of CMV-specific T-cells. The number of A2/pp65 tetramer binding CTLs in blood may prove to be clinically relevant in assessing the immune response to CMV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868621     DOI: 10.1097/00007890-200006150-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

Review 1.  Development and use of multimeric major histocompatibility complex molecules.

Authors:  Tim F Greten; Jonathan P Schneck
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Crystallization and preliminary X-ray crystallographic characterization of a public CMV-specific TCR in complex with its cognate antigen.

Authors:  Jean Baptiste Reiser; François Legoux; Paul Machillot; Emilie Debeaupuis; Béatrice Le Moullac-Vaydie; Anne Chouquet; Xavier Saulquin; Marc Bonneville; Dominique Housset
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-10-30

Review 3.  Cytomegalovirus and the aging population.

Authors:  V C Emery
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.

Authors:  A Samri; C Durier; A Urrutia; I Sanchez; H Gahery-Segard; S Imbart; M Sinet; E Tartour; J-P Aboulker; B Autran; A Venet
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 5.  Investigation of CMV disease in immunocompromised patients.

Authors:  V C Emery
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

6.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Authors:  K L Knutson; K Schiffman; M L Disis
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

7.  BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.

Authors:  J Merino; N Ramírez; C Moreno; E Toledo; M Fernández; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

8.  Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment.

Authors:  M Engstrand; A K Lidehall; T H Totterman; B Herrman; B-M Eriksson; O Korsgren
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

9.  Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.

Authors:  Jie Zhong; Michael Rist; Leanne Cooper; Corey Smith; Rajiv Khanna
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

10.  Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells.

Authors:  Li-Xin Wang; Wen-Xin Huang; Hallie Graor; Peter A Cohen; Julian A Kim; Suyu Shu; Gregory E Plautz
Journal:  J Transl Med       Date:  2004-11-26       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.